SCHEMBL146154

SCHEMBL146154

COc1cccc(C(C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.52
CYP3A4 P08684 2/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 2/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
STAT1 P42224 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
TP53 P04637 1/20 0.47
KIF11 P52732 1/20 0.47
SOD1 P00441 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29893927 0.98 ACHE (0.50) ACHECYP3A4LMNAHTTNPC1
SCHEMBL13009187 0.92 SMN1; SMN2 (0.55) ACHECYP3A4LMNAHTTNPC1
SCHEMBL16663957 0.88 KIF11 (0.55) ACHECYP3A4LMNAHTTNPC1
Phenol SCHEMBL28262366 0.87 KIF11 (0.47) ACHECYP3A4LMNAHTTNPC1
SCHEMBL8408204 0.86 ACHE (0.52) ACHECYP3A4LMNAHTTNPC1
SCHEMBL278328 0.86 LTA4H (0.55) CYP3A4LMNAHTTNPC1MAPT
SCHEMBL19326347 0.84 SOD1 (0.47) ACHECYP3A4LMNAHTTNPC1
SCHEMBL18118971 0.84 CYP3A4 (0.59) ACHECYP3A4LMNAHTTNPC1
SCHEMBL28407343 0.84 CYP3A4 (0.50) ACHECYP3A4LMNAHTTNPC1
SCHEMBL13439849 0.83 MAOB (0.61) NPC1RAB9ASOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114317448-A Hybridoma cell strain secreting anti-etoxazole monoclonal antibody and application thereof 无锡迪腾敏生物科技有限公司 2022-04-12 CN claimed
WO-2020210428-A1 NOVEL INHIBITORS OF FLAVIVIRUS PROTEASE FOR PREVENTION AND TREATMENT OF ZIKA, DENGUE AND OTHER FLAVIVIRUS INFECTIONS BAYLOR COLLEGE OF MEDICINE (US) 2020-10-15 WO claimed
US-8426115-B2 Patterning process and resist composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2013-04-23 US claimed
US-20110033803-A1 PATTERNING PROCESS AND RESIST COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2011-02-10 US claimed
EP-1733450-B1 REDOX SHUTTLE FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES CO (US) 2010-12-08 EP claimed
US-7811710-B2 Redox shuttle for rechargeable lithium-ion cell 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-10-12 US claimed
US-20100159392-A1 PATTERNING PROCESS AND RESIST COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2010-06-24 US claimed
EP-1733450-A2 REDOX SHUTTLE FOR RECHARGEABLE LITHIUM-ION CELL 3M Innovative Properties Company (US) 2006-12-20 EP claimed
WO-2005099024-A2 REDOX SHUTTLE FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-10-20 WO claimed
US-20050221196-A1 Redox shuttle for rechargeable lithium-ion cell 3M INNOVATIVE PROPERTIES COMPANY 2005-10-06 US claimed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 US disclosed
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2025-02-20 US disclosed
WO-1998040339-A1 METHOD FOR ACYLATION OR SULPHONATION OF AN AROMATIC COMPOUND RHODIA CHIMIE (FR) 1998-09-17 WO disclosed
US-5637773-A FORMING HYDROXY-AND/OR ALKOXYAROMATIC ALKYLKETONES RHONE-POULENC CHIMIE (FR) 1997-06-10 US disclosed
EP-0698593-A1 Process for the acylation of an aromatic compound RHONE-POULENC CHIMIE (FR) 1996-02-28 EP disclosed
US-4837301-A FROM ALKALI MTEAL SULFIDES AND AROMATIC DIHALOGEN COMPOUNDS; IMPROVED CORROSION RESISTANCE BAYER AKTIENGESELLSCHAFT (DE) 1989-06-06 US disclosed
EP-0275007-A2 Process for the preparation of highly molecular, optionally branched polyarylene sulfides BAYER AG (DE) 1988-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B ACHE 3810/4885CYP3A4 4298/4885LMNA 4112/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B ACHE 3810/4885CYP3A4 4298/4885LMNA 4112/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B ACHE 3897/4885CYP3A4 3304/4885LMNA 3385/4885
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS KAT6A, KAT2A, KAT6B ACHE 3547/4885CYP3A4 3135/4885LMNA 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.